DRMA Dermata Therapeutics (DRMA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001853816
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about DRMA
Insiders, 180 days
-$13 net sold
1 seller · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
1 filing
Largest: 9.0% of the class
Dermata Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Dermata Therapeutics, Inc. insiders sold a net $13 of stock across 6 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Scott Kathleen D. sold about $13 of DRMA on Jun 16, 2026, the largest insider sale at the company on our record; 9 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 98.8% of the 1,012 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought about $1.3K of DRMA on Feb 17, 2026, the largest insider purchase at the company since 2021; 9 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 16, 2021.
- The trade is 33.6% of the 59,512 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO and Chairman PROEHL GERALD T bought about $48.0K of DRMA on Nov 23, 2021; 9 funds added in the latest 13F quarter.6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$13 over 180 days
more than 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.9% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
below 66% of Pharma & Biotech
The situation: each line is one rule over one dataset
Kyri K. Van Hoose disclosed a 5%+ stake (9.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DRMA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-82.8%12M
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DRMA: institutional holders (13F)
13F holdings, latest reported quarter
20,203 sh
$26.1K
20,000 sh
$25.8K
18,747 sh
$24.2K
18,600 sh
$21.7K
15,989 sh
$20.6K
Congress trades in DRMA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Kyri K. Van Hoose
Activist 13D · 2026-06-01
9.0%
DRMA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DRMA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$53.7K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$1.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $13 sold by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DRMA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
current debt only, 2021-12-31 (54 months older than the period end); equity 2026-06-30
Debt to equity DRMA
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-183.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DRMA
| FY Dec 2025 | -194.2% |
| FY Dec 2024 | -310.4% |
| FY Dec 2023 | -126.0% |
| FY Dec 2022 | -119.2% |
| FY Dec 2021 | -228.1% |
| Jun 2026 | -183.9% |
| Mar 2026 | -103.6% |
| Dec 2025 | -194.2% |
| Sep 2025 | -203.4% |
| Jun 2025 | -231.3% |
| Mar 2025 | -206.3% |
| Dec 2024 | -310.4% |
| Sep 2024 | -202.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-139.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DRMA
| FY Dec 2025 | -132.6% |
| FY Dec 2024 | -213.5% |
| FY Dec 2023 | -104.5% |
| FY Dec 2022 | -103.5% |
| FY Dec 2021 | -129.2% |
| Jun 2026 | -139.9% |
| Mar 2026 | -81.3% |
| Dec 2025 | -132.6% |
| Sep 2025 | -150.5% |
| Jun 2025 | -173.9% |
| Mar 2025 | -150.9% |
| Dec 2024 | -213.5% |
| Sep 2024 | -160.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-258.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DRMA
| FY Dec 2025 | -255.0% |
| FY Dec 2024 | -402.9% |
| FY Dec 2023 | -167.1% |
| FY Dec 2022 | -145.8% |
| FY Dec 2021 | -226.8% |
| Jun 2026 | -258.2% |
| Mar 2026 | -121.0% |
| Dec 2025 | -255.0% |
| Sep 2025 | -281.0% |
| Jun 2025 | -320.5% |
| Mar 2025 | -235.7% |
| Dec 2024 | -402.9% |
| Sep 2024 | -264.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.36x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$1.5M
market value at close 2026-10-26 on 2026-08-10 shares, plus current debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
Enterprise value DRMA
| FY Dec 2025 | -$5.1M |
| FY Dec 2024 | $24.4M |
| FY Dec 2023 | $285.2M |
| FY Dec 2022 | $11.9B |
| FY Dec 2021 | $34.8B |
| Jun 2026 | $775.8K |
| Mar 2026 | -$2.1M |
| Dec 2025 | -$5.1M |
| Sep 2025 | -$1.2M |
| Jun 2025 | $30.8M |
| Mar 2025 | $48.9M |
| Dec 2024 | $24.4M |
| Sep 2024 | $15.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing DRMA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M |
| EPS (diluted) | -8.16 | -80.32 | -39.99 | n/a |
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M |
| Cash | $7.5M | $3.2M | n/a | $6.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
DRMA Stock Sonar score 5/7 axes
Find similar shapesCompareDRMA ranks highest on financial health (99th percentile) and risk and compliance (68th), and lowest on institutional and government (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DRMA filings, in plain words
Are Dermata Therapeutics insiders buying or selling DRMA?
In the 180 days to 2026-10-28, Dermata Therapeutics insiders were net sellers, a net $13 across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Dermata Therapeutics insiders were net sellers of DRMA, a net $13 across purchases and sales reported on Form 4 by 1 seller. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 9.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
